A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor - Test2 - elhamkhani - TriplyDB

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

http://www.wikidata.org/entity/Q24563250

about

Dysphoric milk ejection reflex: A case report Strategies for managing sexual dysfunction induced by antidepressant medication 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL Norepinephrine transporter inhibitors and their therapeutic potential Getting the balance right: Established and emerging therapies for major depressive disorders The outcome of unintentional pediatric bupropion ingestions: a NPDS database review Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant A clinical perspective of obesity, metabolic syndrome and cardiovascular disease The New Era of Drug Therapy for Obesity: The Evidence and the Expectations Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine A brief history of the development of antidepressant drugs: from monoamines to glutamate Mechanistic insights into nicotine withdrawal.Abuse and misuse of antidepressants Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials Seizures after overdoses of bupropion intake The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder Effects of treatment for tobacco dependence on resting cerebral glucose metabolism.Synthesis, screening and pharmacokinetic evaluation of potential prodrugs of bupropion. Part one: in vitro development.Structural alterations in the prefrontal cortex mediate the relationship between Internet gaming disorder and depressed mood Bupropion Administration Increases Resting-State Functional Connectivity in Dorso-Medial Prefrontal Cortex.Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Reconsidering anhedonia in depression: lessons from translational neuroscience.Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence The efficacy and tolerability of bupropion in the treatment of major depressive disorder.Bupropion for the treatment of seasonal affective disorder.Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study.Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism.Characterization of the transporterB0AT3 (Slc6a17) in the rodent central nervous system.Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence.Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers.Treatment of maternal depression in a medication clinical trial and its effect on children.Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.Bupropion-Induced Erythema Multiforme.Effect of comedication of bupropion and other antidepressants on body mass index.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.The Role of the Habenula in Nicotine Addiction.

P2860

Q21203591-832FF444-257F-4246-A0F1-0DC7340FC1EB Q24202675-E789CDA4-4BD2-4294-9924-6AE65FB075CB Q24530904-6B145A1C-1952-45C8-A016-88697F908A2B Q24554381-5428E4E2-4F88-46F9-9A51-B92F0F2FED87 Q24610225-FA06D837-7BA5-40C1-A2A8-BB2C754498B9 Q24631523-3527C908-2660-40CE-9A34-36247D297CD7 Q26747727-6A40388D-8A3D-42AF-927F-90FA7036427C Q26753121-09C3E105-70E0-4DCA-B36C-AE6D75376BBE Q26827555-B54A593F-A5E3-4CAD-911A-7EBFF439E731 Q26864531-0B0ACBAC-AE1E-4397-A240-D10A0D1518CD Q27028050-D088C930-EBB9-4AFB-88E0-D3CBC4245580 Q27687645-9E5F09F6-005B-4F80-A71F-9A9353BA90D3 Q27691354-3F14993D-7C78-4A94-B76F-4FEDC6BBA0CD Q28252146-1124729E-4314-44A1-B3AB-4EACD9A4599E Q28391339-C8E9FA5F-E901-4462-B203-B2371AD7CE19 Q30278438-1CC6E6B7-36B9-42FB-A16B-2ED90E155C3E Q33600358-AFB1D00D-357F-4C1C-86A4-583C7FFD3005 Q33620732-BE020DBF-71BE-46E3-831D-14C4D3DD191D Q33673177-B987A7B8-4538-4F83-B465-B5FF5129BB4D Q33682148-791943CA-F3F5-40CB-8204-A5656F7113B1 Q33762264-A7D4822B-7F03-4662-A04B-26DCD59BD07B Q33803436-C12F19CB-8DC4-4884-AC68-47553AD8D2EE Q34124371-B7AD7214-240F-4CAA-A06F-E48A8606B163 Q34164210-22B0F8E3-09A5-43D0-82ED-B9B71AB74E0A Q34226014-15AEA5D1-4D1A-443A-AB37-BEC2B9EC6F1F Q34346558-1ABB6F9D-131E-40DE-958C-329A3AB8C515 Q34540994-0048E403-9A7B-4A4B-A073-103F016AE581 Q34541188-3143BAB1-2169-4DCC-A4A0-AE46DC242332 Q34547482-FE3A763E-CCD8-4D0E-9479-5AF08BA53F54 Q34659646-067AA0DD-2EE6-45BD-B46F-05FF26EDF039 Q34660100-D42C8020-AD73-4099-8121-09F3F8207EFC Q34721980-88A9CEDB-B461-40DD-94BC-FD4D9A23A2D6 Q34756340-B1D67B67-BD7A-4676-9F24-E912F67DB476 Q35545542-22F814AB-6138-4457-8667-54E565CDC340 Q35561691-A11AA75D-A5AE-40BF-8EAB-B1BE39206FB4 Q35695148-93B7CE95-80A1-42DC-A2D1-371C69AA54F1 Q35739277-FB919DD4-1DD3-4189-8C56-E1354FE3884D Q35852531-C7257726-750E-4963-91B7-E2E77D4C0561 Q35862776-0A968A6A-81F5-49C6-8340-2814D5E90049 Q35875345-20461831-969E-4F68-BF37-61F5BF21953E

P2860

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

http://www.wikidata.org/entity/Q24563250

description

2004 nî lūn-bûn

@nan

2004 թուականին հրատարակուած գիտական յօդուած

@hyw

2004 թվականին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@ast

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@en

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@nl

type

label

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@ast

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@en

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@nl

prefLabel

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@ast

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@en

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@nl

P1433

Q24563250-727C60F1-793E-4563-8B28-BFD6CE53BDCD

P1476

Q24563250-7F9D78DF-E871-4130-B93E-6F8D4032856C

P2093

Q24563250-102F09AF-AF49-4A2B-81DD-215EADA6BEB6

Q24563250-17C60E7C-D532-40EE-AD04-C619AC37E373

Q24563250-56D0627D-84C0-4A45-B45A-74CFDF5FC5BB

Q24563250-A38C1C1A-B1EC-4840-A3A7-F730D89CC13E

Q24563250-A8909485-4A12-4803-96CB-7477E81FF26A

Q24563250-C7C0D879-6FB2-4577-B8FD-376D54FE96B6

P2860

Q24563250-0490105A-2F69-4F3F-AFCE-72DA2D2EE44C

Q24563250-0A6282DD-7F45-4CA1-97FF-3A005E35D585

Q24563250-0F0E48C2-D645-4B0F-98F5-AE109BFC8090

Q24563250-114DA96E-2537-424D-87B2-D1D37BE54092

Q24563250-15F42830-BA9D-458A-BAED-363DC93128DA

Q24563250-283076F5-FDD5-4BFF-9B98-49EBD5053238

Q24563250-2BA55257-EA01-4E7D-B339-210CE821766F

Q24563250-2BB76581-04FB-464E-B7F3-3DB75F8B80AA

Q24563250-3ACBFEE8-5139-404C-95BC-C5AB45DB1E68

Q24563250-4021DEED-0D7A-47EA-9484-28C5A6596894

P304

Q24563250-DC19C42A-3B98-4667-A57F-D1B063DB418E

P31

Q24563250-70D11873-F974-4FFE-8B18-504F00064F9F

P3181

Q24563250-C5DA247F-75C8-4A37-AD0D-06FD28040E6B

P356

Q24563250-407AD5C0-C2A6-455C-B18E-D3ABD855777B

P407

Q24563250-5F478DD7-452F-4EFC-91A4-05CCAE48630F

P433

Q24563250-7910DC07-4A76-414F-AD87-01A704CC9BF0

P478

Q24563250-3A8E1A49-C168-434C-8F34-B91226246086

P577

Q24563250-716607F6-2E43-4D0A-BE89-7C7F73C35543

P5875

Q24563250-B71FA19E-EC00-4905-A21E-67FA3F9388BC

P698

Q24563250-DFE55D7B-F12E-40B7-BCE6-21F0591BBEDF

P921

Q24563250-8ed9589d-3885-44b7-9224-ebc7a34be9b6

Q24563250-af497a4b-dba2-48a7-b7da-0ed6ea908635

P932

Q24563250-C5D29C54-B66C-4B15-B079-52A939F671BC

P3181

P356

P1433

Primary Care Companion to the Journal of Clinical Psychiatry

P1476

A Review of the Neuropharmacol ...... nd Dopamine Reuptake Inhibitor

@en

P2093

Barbara R. Haight

http://www.w3.org/2001/XMLSchema#string

Carol B. Rockett

http://www.w3.org/2001/XMLSchema#string

Jack G. Modell

http://www.w3.org/2001/XMLSchema#string

James F. Pradko

http://www.w3.org/2001/XMLSchema#string

Stephen M. Stahl

http://www.w3.org/2001/XMLSchema#string

Susan Learned-Coughlin

http://www.w3.org/2001/XMLSchema#string

P2860

Untreated Depression and Hippocampal Volume Loss

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.

Prevalence of sexual dysfunction among newer antidepressants.

A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.

Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice.

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.

P304

159-166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2246828

http://www.w3.org/2001/XMLSchema#string

P356

10.4088/PCC.V06N0403

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8352525

http://www.w3.org/2001/XMLSchema#string

P698

15361919

http://www.w3.org/2001/XMLSchema#string

P921

P932

514842

http://www.w3.org/2001/XMLSchema#string